BACKGROUND: Earlier detection of pancreatic adenocarcinoma is needed. OBJECTIVE: To determine whether early pancreatic neoplasia can be detected in a high-risk population by using CA 19-9 followed by targeted EUS. DESIGN: Prospective cohort study. SETTING: Two academic medical centers. PATIENTS: Eligible patients met age criteria and had at least 1 first-degree relative with pancreatic adenocarcinoma. INTERVENTIONS: A serum CA 19-9 was performed on all patients. EUS was performed if the CA 19-9 level was elevated. FNA of identified lesions was performed. Patients with pancreatic cancer detected by using this screening protocol were compared with patients presenting off-protocol for staging data. Medicare reimbursement rates were used to derive cost data. MAIN OUTCOME MEASUREMENTS: Detection of early pancreatic neoplasia. RESULTS: A total of 546 patients were enrolled. CA 19-9 was elevated in 27 patients (4.9%, 95% CI, 3.2%-7.1%). Neoplastic or malignant findings were detected in 5 patients (0.9%, 95% CI, 0.3%-2.1%), and pancreatic adenocarcinoma in 1 patient (0.2%, 95% CI, 0.005%-1.02%). The patient with pancreatic cancer detected as part of this protocol was 1 of 2 patients presenting to the University of Vermont with stage 1 cancer. The cost to detect 1 pancreatic neoplasia was $8431. The cost to detect 1 pancreatic adenocarcinoma was $41,133. LIMITATIONS: The sample size is adequate only to demonstrate the feasibility of this approach. CONCLUSIONS: Potentially curative pancreatic adenocarcinoma can be identified with this screening protocol. Stage 1 pancreatic cancer is more likely to be detected by using this screening protocol than by using standard means of detection.
BACKGROUND: Earlier detection of pancreatic adenocarcinoma is needed. OBJECTIVE: To determine whether early pancreatic neoplasia can be detected in a high-risk population by using CA 19-9 followed by targeted EUS. DESIGN: Prospective cohort study. SETTING: Two academic medical centers. PATIENTS: Eligible patients met age criteria and had at least 1 first-degree relative with pancreatic adenocarcinoma. INTERVENTIONS: A serum CA 19-9 was performed on all patients. EUS was performed if the CA 19-9 level was elevated. FNA of identified lesions was performed. Patients with pancreatic cancer detected by using this screening protocol were compared with patients presenting off-protocol for staging data. Medicare reimbursement rates were used to derive cost data. MAIN OUTCOME MEASUREMENTS: Detection of early pancreatic neoplasia. RESULTS: A total of 546 patients were enrolled. CA 19-9 was elevated in 27 patients (4.9%, 95% CI, 3.2%-7.1%). Neoplastic or malignant findings were detected in 5 patients (0.9%, 95% CI, 0.3%-2.1%), and pancreatic adenocarcinoma in 1 patient (0.2%, 95% CI, 0.005%-1.02%). The patient with pancreatic cancer detected as part of this protocol was 1 of 2 patients presenting to the University of Vermont with stage 1 cancer. The cost to detect 1 pancreatic neoplasia was $8431. The cost to detect 1 pancreatic adenocarcinoma was $41,133. LIMITATIONS: The sample size is adequate only to demonstrate the feasibility of this approach. CONCLUSIONS: Potentially curative pancreatic adenocarcinoma can be identified with this screening protocol. Stage 1 pancreatic cancer is more likely to be detected by using this screening protocol than by using standard means of detection.
Authors: Benjamin F Mann; John A Goetz; Michael G House; C Max Schmidt; Milos V Novotny Journal: Mol Cell Proteomics Date: 2012-03-05 Impact factor: 5.911
Authors: Evan L Fogel; Safi Shahda; Kumar Sandrasegaran; John DeWitt; Jeffrey J Easler; David M Agarwal; Mackenzie Eagleson; Nicholas J Zyromski; Michael G House; Susannah Ellsworth; Ihab El Hajj; Bert H O'Neil; Attila Nakeeb; Stuart Sherman Journal: Am J Gastroenterol Date: 2017-01-31 Impact factor: 10.864
Authors: David V Gold; Jochen Gaedcke; B Michael Ghadimi; Michael Goggins; Ralph H Hruban; Mengling Liu; Guy Newsome; David M Goldenberg Journal: Cancer Date: 2012-08-16 Impact factor: 6.860
Authors: Florencia McAllister; Maria F Montiel; Guneesh S Uberoi; Angad S Uberoi; Anirban Maitra; Manoop S Bhutani Journal: Gastroenterol Hepatol (N Y) Date: 2017-05
Authors: Martin Tobi; Mijin Kim; Douglas H Weinstein; Mary Ann Rambus; James Hatfield; N Volkan Adsay; Edi Levi; Douglas Evans; Michael J Lawson; Suzanne Fligiel Journal: Dig Dis Sci Date: 2012-09-22 Impact factor: 3.199